Camrelizumab: First Global Approval

This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.

http://link.springer.com/10.1007/s40265-019-01167-0

Source: Drugs - July 15, 2019 Category: Drugs & Pharmacology Source Type: research

More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Drugs & Pharmacology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Lung Cancer | Lymphoma | Nasopharyngeal Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma